+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plant-based Biologics and Expression Systems Market by Type of Product, Type of Plant, Type of Service, Type of Expression System, Type of Target Disease Indication, Type of Therapeutic Area, Drug, and Region: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 155 Pages
  • February 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557817
A significant rise in the popularity of biologics has been observed over the years. The demand for such treatment modalities further witnessed a surge post the onset of the COVID-19 pandemic. At present, about 85% of the drug candidates are produced using mammalian cell cultures. However, such systems are associated with a number of challenges; these include risk of introducing pathogens, concerns related to scale-up, decrease in productivity and rise in byproduct formation. It is also worth highlighting that research indicates that the existing mammalian cell capacities are likely to fulfill only 50% of the inflated demand (due to COVID-19) for biologics. In this context, owing to some major advances in synthetic organic chemistry, plant based expression systems have emerged as a promising alternative for the development of biologics. It is worth mentioning that plant-host engineering allows the production of proteins with distinct and uniform post-translational modifications, allowing the development of biologics, which demonstrate higher effectiveness, as compared to those produced using other protein expression systems, such as mammalian or yeast-based cell cultures. Plant-based biologics are safer, as they pose negligible risk of introducing human and animal pathogens in the therapy candidates. Additionally, plant molecular farming has the ability to facilitate rapid (4-8 weeks) plant-based biologics manufacturing at a large scale (several grams), as well as to meet the emergency demands (as observed in the case of COVID-19 pandemic). Moreover, the running costs of a GMP plant-based manufacturing facility are reported to be 25% less than those using other expression systems.

Given the aforementioned factors, pharmaceutical players are actively adopting plant-based expression systems for the production of various recombinant proteins. A wide range of vaccine candidates, plant-based enzymes, therapeutic proteins (including monoclonal antibodies) and nutritional proteins have also been produced via transgenic and transient expression in entire plants or plant cell cultures. Currently, close to 50 plant-based therapies have been developed / are being evaluated and more than 35 plant-based expression system providers are actively offering their proprietary technologies to drug developers. Multiple partnerships between industry and non-industry stakeholders, focused on the development of plant-based therapies, have been established. Driven by increasing prevalence of disease indications, growing demand for biologics, the ongoing efforts being carried out to advance the development of such products, as well as further optimize the associated technologies, the global plant-based biologics market is likely to grow at a healthy rate, in the foreseen future.


Scope of the Report



The “Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Service (Research and Development, Manufacturing, Fill / Finish and Others), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp), and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of plant-based therapies in the pharmaceutical industry, over the next 13 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. 


Amongst other elements, the report includes:


  • A detailed overview of the current market landscape of plant-based expression system providers, including information on some relevant parameters such as the type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product (antibodies (unspecified), biosimilars, cell therapies, gene therapies, monoclonal antibodies, proteins (unspecified), vaccines and others), type of service (R&D, manufacturing, fill / finish, and others) and type of expression system (transient and stable). Additionally, it highlights information on plant-based expression system providers, including details related to their respective year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary technologies.
  • A detailed overview of the current market landscape of plant-based biologics, including information on their status of development (marketed, clinical and preclinical), target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher Disease, liver cirrhosis, influenza, and peanut allergy), therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others) and type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). Additionally, it highlights the developers of these novel therapeutics, including details on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.
  • Elaborate profiles of key players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to its technology portfolio, recent developments, and an informed future outlook.
  • An analysis of the recent partnerships and collaborations that have been inked between various stakeholders in the domain, during the period between 2017 and 2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions and others. 
  • An insightful company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in offering plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). It also includes a benchmarking analysis of systems providers based on their portfolio strength and partnership activity.
  • An insightful publication analysis, which includes analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. Additionally, it features key trends observed across the aforementioned publications, including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and key timelines. Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of article, grant support, journal impact factor and timeline of publications.
One of the key objectives of the report was to estimate the existing size and the future opportunity associated with the plant-based biologics and expression systems market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates, expected pricing and R&D expenditure, we have provided informed estimates on the financial evolution of the market for the period 2022-2035. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines and others [B] type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco and wheat germ), [C] type of service (research and development, manufacturing, fill / finish and others), [D] type of expression system (stable expression system and transient expression system) [E] target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy) [F] therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others) [G] drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and [H] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the key players engaged in providing plant-based expression systems?
  • What are the key plant sources utilized by drug developers to manufacture plant-based biologics?
  • Which are the key therapeutic areas for which plant-based biologics are being developed?
  • What are the different proprietary technologies of plant-based expression system providers?
  • What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • What is the relative competitiveness of different plant-based expression system providers?
  • What is the evolving trend related to the focus of publications related to plant-based biologics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Plant-based Biologics and Expression Systems
3.2. Classification of Plant-based Expression Platforms
3.3. Advantages of Plant-based Bioproduction Systems
3.4. Commonly used Plant-based Bioproduction Systems
3.5. Mechanism of Plant Expression Platform
3.6. Recent Developments
3.7. Future Perspective
4. PLANT-BASED EXPRESSION SYSTEMS: MARKET LANDSCAPE
4.1. Plant-based Expression Systems: Market Landscape
4.2. Plant-based Expression Systems: List of Providers
4.2.1. Analysis by Type of Plant
4.2.2. Analysis by Type of Biologic
4.2.3. Analysis by Type of Plant and Type of Biologic
4.2.4. Analysis by Type of Biologic and Region
4.2.5. Analysis by Type of Plant, Type of Biologic and Region
4.2.6. Analysis by Type of Service
4.2.7. Analysis by Year of Establishment
4.2.8. Analysis by Company Size
4.2.9. Analysis by Region (Country-wise)
4.2.10. Analysis by Region (Continent-wise)
5. PLANT-BASED BIOLOGICS: MARKET LANDSCAPE
5.1. Plant-based Biologics: Pipeline Review
5.2. Plant-based Biologics: List of Drug Candidates
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Target Disease Indication
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Status of Development and Therapeutic Area
5.2.5. Analysis by Type of Product
5.2.6. Analysis by Status of Development and Type of Product
5.3. Plant-based Biologics: List of Drug Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Region
5.3.3.1. Analysis of Developers in North America
5.3.3.2. Analysis of Developers in Europe
5.3.3.3. Analysis of Developers in Rest of the World
6. COMPANY PROFILES
6.1. Medicago
6.1.1. Company Overview
6.1.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.2. Leaf Expression Systems
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Eleva
6.3.1. Company Overview
6.3.2. Technology Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. iBIO
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PlantForm
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. G+Flas Life Sciences
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Kentucky Bioprocessing
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Kentucky Bioprocessing
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Angany
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Plant-based Biologics and Expression Systems: Partnerships and Collaborations
7.1.1. Analysis by Year of Partnership
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Type of Biologic
7.1.5. Analysis by Type of Partnership and Type of Biologic
7.1.6. Key Players: Analysis by Number of Partnerships
7.1.7. Analysis by Partner Headquarters (Region)
7.1.8. Analysis by Region and Type of Agreement
7.1.9. Intercontinental and Intracontinental Deals
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Plant-based Expression System Providers: Company Competitiveness Analysis
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Benchmarking of Portfolio Strength
8.5. Benchmarking of Partnership Strength
8.6. Company Competitiveness Analysis: Small Companies
8.7. Company Competitiveness Analysis: Mid-sized Companies
8.8. Company Competitiveness Analysis: Large Companies
9. PUBLICATIONS ANALYSIS
9.1. Plant-based Biologics and Expression Systems: Publications Analysis
9.2. Assumptions and Key Parameters
9.3. Methodology
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Article Type
9.3.3. Analysis by Journal Title
9.3.4. Analysis by Grant Awarded
9.3.5. Analysis by Primary Funding Body
9.3.6. Analysis by Publisher
9.3.7. Analysis by Primary Author
9.3.8. Analysis by Journal Impact Factor
9.3.9. Analysis by Timeline of Approval
9.3.9.1. Analysis by Article Type and Timeline of Receival, Acceptance and Approval
9.3.9.2. Analysis by Journal Impact Factor and Timeline of Receival, Acceptance and Approval
9.3.9.3. Analysis by Grant Awarded and Timeline of Receival, Acceptance and Approval
9.3.10. Benchmarking Analysis
10. PLANT-BASED EXPRESSION SYSTEMS: MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Key Assumptions and Forecast Methodology
10.2. Global Plant-based Expression Systems Market, 2022-2035
10.3. Plant-based Expression Systems Market: Analysis by Product, 2022 and 2035
10.3.1. Plant-based Expression Systems Market for Biosimilars, 2022-2035
10.3.2. Plant-based Expression Systems Market for Cell Therapies, 2022-2035
10.3.3. Plant-based Expression Systems Market for Gene Therapies, 2022-2035
10.3.4. Plant-based Expression Systems Market for Monoclonal Antibodies, 2022-2035
10.3.5. Plant-based Expression Systems Market for Vaccines, 2022-2035
10.3.6. Plant-based Expression Systems Market for Others, 2022-2035
10.4. Plant-based Expression Systems Market: Analysis by Plant, 2022 and 2035
10.4.1. Plant-based Expression Systems Market for Algae, 2022-2035
10.4.2. Plant-based Expression Systems Market for Barley, 2022-2035
10.4.3. Plant-based Expression Systems Market for Benth, 2022-2035
10.4.4. Plant-based Expression Systems Market for Duckweed, 2022-2035
10.4.5. Plant-based Expression Systems Market for Lettuce, 2022-2035
10.4.6. Plant-based Expression Systems Market for Maize, 2022-2035
10.4.7. Plant-based Expression Systems Market for Moss, 2022-2035
10.4.8. Plant-based Expression Systems Market for Rice, 2022-2035
10.4.9. Plant-based Expression Systems Market for Tomato, 2022-2035
10.4.10. Plant-based Expression Systems Market for Tobacco, 2022-2035
10.4.11. Plant-based Expression Systems Market for Wheat Germ, 2022-2035
10.5. Plant-based Expression Systems Market: Analysis by Type of Service, 2022 and 2035
10.5.1. Plant-based Expression Systems Market for Research and Development, 2022-2035
10.5.2. Plant-based Expression Systems Market for Manufacturing, 2022-2035
10.5.3. Plant-based Expression Systems Market for Fill / Finish, 2022-2035
10.5.4. Plant-based Expression Systems Market for Others, 2022-2035
10.6. Plant-based Expression Systems Market: Analysis by Expression System, 2022 and 2035
10.6.1. Plant-based Expression Systems Market for Stable Expression System, 2022-2035
10.6.2. Plant-based Expression Systems Market for Transient Expression System, 2022-2035
10.7. Plant-based Expression Systems Market: Analysis by Region, 2022 and 2035
10.7.1. Plant-based Expression Systems Market in North America, 2022-2035
10.7.2. Plant-based Expression Systems Market in Europe, 2022-2035
10.7.3. Plant-based Expression Systems Market in Asia, 2022-2035
10.7.4. Plant-based Expression Systems Market in Latin America, 2022-2035
10.7.5. Plant-based Expression Systems Market in MENA, 2022-2035
10.7.6. Plant-based Expression Systems Market in Rest of the World, 2022-2035
11. PLANT-BASED BIOLOGICS: MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Key Parameters and Assumptions
11.2. Forecast Methodology
11.3. Global Plant-based Biologics Market, 2022-2035
11.4. List of Forecasted Drugs
11.4.1. Elelyso, Protalix Biotherapeutics
11.4.1.1. Sales Forecast
11.4.1.2. Net Present Value
11.4.1.3 Value Creation Analysis
11.4.2. OsrHSA, Healthgen Biotechnology
11.4.2.1 Sales Forecast
11.4.2.2. Net Present Value
11.4.2.3. Value Creation Analysis
11.4.3. PALFORZIA, Aimmune Therapeutics
11.4.3.1. Sales Forecast
11.4.3.2. Net Present Value
11.4.3.3. Value Creation Analysis
11.4.4. PRX-110, Protalix Biotherapeutics
11.4.4.1. Sales Forecast
11.4.4.2. Net Present Value
11.4.4.3. Value Creation Analysis
11.4.5. PRX-102, Protalix Biotherapeutics
11.4.5.1. Sales Forecast
11.4.5.2. Net Present Value
11.4.5.3. Value Creation Analysis
11.4.6. Unnamed_1, Medicago
11.4.6.1. Sales Forecast
11.4.6.2. Net Present Value
11.4.6.3. Value Creation Analysis
11.4.7. Unnamed_2, Medicago
11.4.7.1. Sales Forecast
11.4.7.2. Net Present Value
11.4.7.3. Value Creation Analysis
11.4.8. ZMapp, Mapp Biopharmaceutical
11.4.8.1. Sales Forecast
11.4.8.2. Net Present Value
11.4.8.3. Value Creation Analysis
11.5. Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
11.5.1. Plant-based Biologics Market for Cirrhotic Ascites, 2022-2035
11.5.2. Plant-based Biologics Market for COVID-19, 2022-2035
11.5.3 Plant-based Biologics Market for Cystic Fibrosis, 2022-2035
11.5.4 Plant-based Biologics Market for Ebola Virus Infection, 2022-2035
11.5.5. Plant-based Biologics Market for Fabry Disease, 2022-2035
11.5.6. Plant-based Biologics Market for Gaucher Disease, 2022-2035
11.5.7. Plant-based Biologics Market for Influenza, 2022-2035
11.5.8. Plant-based Biologics Market for Liver Cirrhosis, 2022-2035
11.5.9. Plant-based Biologics Market for Peanut Allergy, 2022-2035
11.6. Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
11.6.1. Plant-based Biologics Market for Genetic Disorders, 2022-2035
11.6.2 Plant-based Biologics Market for Infectious Disorders, 2022-2035
11.6.3 Plant-based Biologics Market for Liver Disorders, 2022-2035
11.6.4. Plant-based Biologics Market for Respiratory Disorders, 2022-2035
11.6.5. Plant-based Biologics Market for Others, 2022-2035
11.7. Plant-based Biologics Market: Analysis by Region, 2022 and 2035
11.7.1. Plant-based Biologics Market in North America, 2022-2035
11.7.2. Plant-based Biologics Market in Europe, 2022-2035
11.7.3. Plant-based Biologics Market in Asia, 2022-2035
11.7.4. Plant-based Biologics Market in Rest of the World, 2022-2035
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Transactiva
13.1.1. Company Snapshot
13.1.2. Interview Transcript: Sara Raccovelli (Researcher)
13.2. ORF Genetics
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Júlíus B Kristinsson (Chief Project Manager, Business Development & Co-Founder)
14. APPENDIX 1: TABULATED DATA15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

  • Agrenvec
  • Angany
  • Australian National University (ANU)
  • atbtherapeutics
  • AzarGen Biotechnologies
  • Baiya Phytopharm
  • BC Partners
  • BGM Pharmaceuticals
  • Bill and Melinda Gates Foundation 
  • Bio-Manguinhos
  • Oswaldo Cruz Foundation (Fiocruz)
  • BioMed Central
  • Caliber Biotherapeutics
  • Cape Biologix Technologies
  • Carnegie Corporation of New York 
  • CC-Pharming (Also known as Ruicheng Haihui Biotechnology)
  • CellFree Sciences
  • Chiesi Farmaceutici
  • Corteva Agriscience
  • Council for Scientific and Industrial Research (CSIR)
  • Creative Biolabs
  • Defence Research & Development Canada
  • Defyrus
  • Dow AgroSciences
  • Dynavax Technologies
  • EdgePoint AI
  • Eleva
  • Elsevier
  • ERS Genomics
  • Eversea
  • Fraunhofer Society
  • Frontiers
  • G+FLAS Life Sciences
  • GenScript
  • GlaxoSmithKline
  • Government of Canada
  • Healthgen Biotechnology
  • HotHouse BioEngineering
  • iBio
  • Icon Genetics
  • Inno-3B
  • John Wiley and Sons
  • Kentucky Bioprocessing
  • Leaf Expression Systems
  • LenioBio
  • Lincoln Diagnostics
  • Lung Biotechnology
  • McMaster University
  • MDPI
  • Medicago
  • National Collaborative Research Infrastructure Strategy 
  • Australian Plant Phenomics Facility 
  • National Institute of Allergy and Infectious Diseases
  • National Institute of General Medical Sciences
  • National Natural Science Foundation of China 
  • Nature Publishing 
  • National Institutes of Health 
  • Nomad Bioscience
  • ORF Genetics
  • Oxford University Press
  • PBL Technology 
  • Pfizer
  • Phylloceuticals
  • PlantForm
  • Poliomyelitis Research Foundation 
  • POSCO 
  • ProdiGene
  • Profacgen
  • Protalix Biotherapeutics
  • Public Library of Science
  • RubrYc Therapeutics
  • Safi Biosolutions
  • Samabriva
  • SarcoMed USA
  • Sigma-Aldrich
  • Solarvest BioEnergy
  • St George’s University of London
  • Synthon
  • Takara Bio
  • Transactiva
  • US Department of Defense 
  • Unibio
  • Universite? de Montre?al
  • University of Alberta
  • University of Guelph
  • University of Wisconsin-Madison
  • Ventria Bioscience
  • Wilfrid Laurier University
  • Zea Biosciences
  • Zukunftsfonds Heilbronn

Methodology

 

 

Loading
LOADING...